MacuLogix Appoints McPhee to Succeed Edwards as Chief Executive Officer

By

William McPhee, CEO of MacuLogix
MIDDLETOWN, Pa.—MacuLogix Inc., a pioneer in the early detection and tracking of retinal diseases, has appointed William McPhee as chief executive officer, effective Dec. 19. According to a company statement, McPhee continues as director of the company, a role he has held since 2012.

McPhee succeeds John Edwards, who has stepped down from his roles as chief executive officer and director.

In the MacuLogix statement, Tracy Saxton, an investment director for Roche Venture Fund, the lead investor in MacuLogix said, “Bill McPhee has a proven track record of building businesses and a true passion for vision-related technology. As a long-term investor in MacuLogix, we are excited to support Bill as he builds on the success the company has achieved under the leadership of John Edwards.”

McPhee, who has held posts with Bain & Company and PepsiCo, among other companies, has 35 years of experience in strategy and operations consulting, fund-raising, transactions and venture capital, according to the statement. He founded and exited two companies and served as chief executive of eSight Corp., where he led the commercialization of electronic eyewear that enables the legally blind to see.

“It is an honor to be appointed CEO of MacuLogix at this exciting stage in the company’s growth,” McPhee said.

MacuLogix, an innovator in the early detection and tracking of age-related macular degeneration, has developed AdaptDx, the first practical device for detecting age-related macular degeneration (AMD) at least three years earlier than other technology, according to the company.